Jay Olson
Stock Analyst at Oppenheimer
(4.29)
# 514
Out of 4,412 analysts
173
Total ratings
46.91%
Success rate
17.29%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Outperform | $200 | $135.99 | +47.07% | 10 | Apr 24, 2024 | |
| INCY Incyte | Maintains: Outperform | $92 → $84 | $51.68 | +62.54% | 8 | Apr 24, 2024 | |
| BIIB Biogen | Maintains: Outperform | $290 → $270 | $208.90 | +29.25% | 18 | Apr 19, 2024 | |
| SAGE Sage Therapeutics | Maintains: Perform | $25 → $17 | $13.69 | +24.18% | 7 | Apr 18, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $43 → $45 | $35.96 | +25.14% | 6 | Apr 12, 2024 | |
| SKYE Skye Bioscience | Initiates: Outperform | $25 | $13.00 | +92.31% | 1 | Apr 12, 2024 | |
| QTTB Q32 Bio | Initiates: Outperform | $50 | $28.02 | +78.44% | 1 | Apr 11, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $72 → $75 | $41.59 | +80.33% | 3 | Apr 9, 2024 | |
| STRO Sutro Biopharma | Maintains: Outperform | $10 | $3.42 | +192.40% | 4 | Apr 3, 2024 | |
| VKTX Viking Therapeutics | Maintains: Outperform | $116 → $138 | $74.31 | +85.71% | 7 | Mar 27, 2024 | |
| CGTX Cognition Therapeutics | Maintains: Outperform | $9 | $1.95 | +361.54% | 4 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $320 → $375 | $193.33 | +93.97% | 7 | Mar 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $25 → $19 | $16.71 | +13.70% | 10 | Mar 12, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Perform | $9 | $1.41 | +540.57% | 4 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 | $20.40 | +292.16% | 4 | Mar 7, 2024 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.47 | +1,600.68% | 1 | Mar 5, 2024 | |
| ETNB 89bio | Maintains: Perform | n/a | $8.26 | - | 5 | Mar 5, 2024 | |
| PRTA Prothena Corporation | Maintains: Outperform | $98 → $80 | $20.87 | +283.33% | 8 | Feb 20, 2024 | |
| AMGN Amgen | Reiterates: Outperform | $350 | $269.98 | +29.64% | 16 | Feb 1, 2024 | |
| BIVI BioVie | Maintains: Outperform | $12 → $5 | $0.48 | +931.35% | 4 | Nov 30, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Perform | $25 → $21 | $12.37 | +69.77% | 7 | Nov 22, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $80 → $70 | $20.76 | +237.19% | 7 | Nov 13, 2023 | |
| EXEL Exelixis | Maintains: Outperform | $25 → $29 | $23.70 | +22.36% | 3 | Aug 22, 2023 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Outperform | $102 | $53.91 | +89.20% | 5 | Aug 10, 2023 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | $16 | $7.62 | +109.97% | 4 | Aug 7, 2023 | |
| EDIT Editas Medicine | Reiterates: Perform | $12 | $5.32 | +125.56% | 5 | Aug 3, 2023 | |
| GLTO Galecto | Reiterates: Outperform | $12 | $0.70 | +1,602.61% | 2 | Aug 1, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $70 → $68 | $15.43 | +340.70% | 3 | Jun 6, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Outperform | $55 | $22.71 | +142.18% | 2 | May 8, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Perform | $5 → $3 | $1.32 | +127.27% | 2 | Mar 6, 2023 | |
| RLMD Relmada Therapeutics | Downgrades: Perform | n/a | $3.83 | - | 2 | Oct 13, 2022 | |
| MDWD MediWound | Maintains: Outperform | n/a | $18.24 | - | 1 | Mar 20, 2018 | |
| TXMD TherapeuticsMD | Upgrades: Outperform | n/a | $1.86 | - | 2 | Jul 11, 2017 |
Neurocrine Biosciences
Apr 24, 2024
Maintains: Outperform
Price Target: $200
Current: $135.99
Upside: +47.07%
Incyte
Apr 24, 2024
Maintains: Outperform
Price Target: $92 → $84
Current: $51.68
Upside: +62.54%
Biogen
Apr 19, 2024
Maintains: Outperform
Price Target: $290 → $270
Current: $208.90
Upside: +29.25%
Sage Therapeutics
Apr 18, 2024
Maintains: Perform
Price Target: $25 → $17
Current: $13.69
Upside: +24.18%
Revolution Medicines
Apr 12, 2024
Maintains: Outperform
Price Target: $43 → $45
Current: $35.96
Upside: +25.14%
Skye Bioscience
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $13.00
Upside: +92.31%
Q32 Bio
Apr 11, 2024
Initiates: Outperform
Price Target: $50
Current: $28.02
Upside: +78.44%
Ionis Pharmaceuticals
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $41.59
Upside: +80.33%
Sutro Biopharma
Apr 3, 2024
Maintains: Outperform
Price Target: $10
Current: $3.42
Upside: +192.40%
Viking Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $116 → $138
Current: $74.31
Upside: +85.71%
Cognition Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.95
Upside: +361.54%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $320 → $375
Current: $193.33
Upside: +93.97%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Perform
Price Target: $25 → $19
Current: $16.71
Upside: +13.70%
Marinus Pharmaceuticals
Mar 7, 2024
Maintains: Perform
Price Target: $9
Current: $1.41
Upside: +540.57%
Jasper Therapeutics
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $20.40
Upside: +292.16%
Immuneering
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $1.47
Upside: +1,600.68%
89bio
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $8.26
Upside: -
Prothena Corporation
Feb 20, 2024
Maintains: Outperform
Price Target: $98 → $80
Current: $20.87
Upside: +283.33%
Amgen
Feb 1, 2024
Reiterates: Outperform
Price Target: $350
Current: $269.98
Upside: +29.64%
BioVie
Nov 30, 2023
Maintains: Outperform
Price Target: $12 → $5
Current: $0.48
Upside: +931.35%
Enanta Pharmaceuticals
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $12.37
Upside: +69.77%
Intellia Therapeutics
Nov 13, 2023
Maintains: Outperform
Price Target: $80 → $70
Current: $20.76
Upside: +237.19%
Exelixis
Aug 22, 2023
Maintains: Outperform
Price Target: $25 → $29
Current: $23.70
Upside: +22.36%
CRISPR Therapeutics AG
Aug 10, 2023
Reiterates: Outperform
Price Target: $102
Current: $53.91
Upside: +89.20%
Voyager Therapeutics
Aug 7, 2023
Reiterates: Outperform
Price Target: $16
Current: $7.62
Upside: +109.97%
Editas Medicine
Aug 3, 2023
Reiterates: Perform
Price Target: $12
Current: $5.32
Upside: +125.56%
Galecto
Aug 1, 2023
Reiterates: Outperform
Price Target: $12
Current: $0.70
Upside: +1,602.61%
Denali Therapeutics
Jun 6, 2023
Maintains: Outperform
Price Target: $70 → $68
Current: $15.43
Upside: +340.70%
Bicycle Therapeutics
May 8, 2023
Reiterates: Outperform
Price Target: $55
Current: $22.71
Upside: +142.18%
Nektar Therapeutics
Mar 6, 2023
Maintains: Perform
Price Target: $5 → $3
Current: $1.32
Upside: +127.27%
Relmada Therapeutics
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.83
Upside: -
MediWound
Mar 20, 2018
Maintains: Outperform
Price Target: n/a
Current: $18.24
Upside: -
TherapeuticsMD
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.86
Upside: -